Johnson & Johnson reported second-quarter sales of $25.31 billion on Wednesday, July 15, 2026, exceeding analyst expectations and raising its full-year financial outlook. The healthcare giant's revenue grew 6.6% from the same period last year, driven by strong performance in its pharmaceutical division.